|52 Week Rng||-|
|P/E Ratio (TTM)||-|
|P/E Ratio (Fwd)||-|
|Div & Yield||-|
Portfolio consists of 20 biotechnology/pharmaceutical corporations' stocks. Equal weighting | Passive buy and hold strategy, long term.
Novo Nordisk A/S is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. Novo Nordisk has experience and capabilities to develop even further. It has a low beta of 0.59 and its stock price have grown steadily over the past couple years.
This transaction follows our fund strategy: passively investing in the 25 largest firms in the healthcare sector (NYSE & NASDAQ) by market capitalization. Equal nominal weighing is used in all transactions. For more information: refer to the fund brochure.